Detection of hepatitis C virus antibodies with new recombinant antigens: assessment in chronic liver diseases
Riezu-Boj JI, Parker D, Civeira MP, Phippard D, Corbishley TP, Camps J, Castilla A, Prieto J.
Department of Internal Medicine, University of Navarra, Pamploma, Spain.
A new serological assay to detect antibodies against hepatitis C, based on a recombinant protein (BHC10) which incorporates structural and non-structural viral antigens, was tested in 67 healthy subjects and 409 patients with various forms of liver disease.
Results were compared with the current assay based on the recombinant non-structural viral antigen c100 and with the recently introduced second-generation assay, Ortho2. None of the healthy subjects was positive by any of the assays. In patients with chronic non-A, non-B hepatitis the prevalence of anti-BHC10 was 96.8%, higher than anti-c100 (83.3%, p less than 0.001) and similar to Ortho2 (94.3%). False-positive results were less frequently found when BHC10 was used.
These findings show that assays incorporating structural and non-structural antigens provide higher sensitivity to detect hepatitis C virus infection and they define an almost exclusive role of hepatitis C virus in the genesis of chronic non-A, non-B hepatitis.
CITA DEL ARTÍCULO J Hepatol. 1992 Jul;15(3):309-13